Galimedix, Inc. | Finanzwire

Basculer en Français

8609	Companies
141600	Keywords
77496	Articles
75667	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 04/01/2025 at 09:05, 10 days 1 hour ago

Galimedix Reports Promising Data for Alzheimer's Treatment

Alzheimer's Disease GAL-201 Galimedix Therapeutics Neuroinflammation Amyloid-β Aggregation
PRESS RELEASE

published on 04/01/2025 at 09:00, 10 days 1 hour ago

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects

Alzheimer's Disease Preclinical Data GAL-201 Galimedix Therapeutics Neuroinflammation
BRIEF

published on 03/24/2025 at 15:12, 17 days 19 hours ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta
PRESS RELEASE

published on 03/24/2025 at 15:07, 17 days 19 hours ago

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference

Alzheimer's Disease Galimedix Therapeutics Pre-clinical Data AD/PD 2025 Conference Aβ Aggregation Modulator
BRIEF

published on 12/23/2024 at 17:35, 3 months 18 days ago

Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Phase 2 Study Neuroprotection GAL-101 Dry AMD Geographic Atrophy
PRESS RELEASE

published on 12/23/2024 at 17:30, 3 months 18 days ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy
BRIEF

published on 12/05/2024 at 13:33, 4 months 5 days ago

Galimedix Therapeutics Initiates Phase 1 Study with Oral GAL-101

Alzheimer's Disease Galimedix Therapeutics GAL-101 Dry AMD Phase 1 Study
PRESS RELEASE

published on 12/05/2024 at 13:28, 4 months 5 days ago

Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments

Galimedix Therapeutics Neurodegenerative Diseases GAL-101 Alzheimer's Phase 1 Study
BRIEF

published on 06/10/2024 at 14:05, 10 months ago

Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101

Scientific Advisory Board Galimedix Therapeutics GAL-101 Phase 2 Clinical Study Dry AMD
PRESS RELEASE

published on 06/10/2024 at 14:00, 10 months ago

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Galimedix Therapeutics forms Scientific Advisory Board of retina experts to guide Phase 2 study with GAL-101 eye drops for dry AMD, addressing unmet medical need

Scientific Advisory Board Galimedix Therapeutics Phase 2 Study Dry AMD Retina Experts

Accesswire

Published on 04/11/2025 at 02:40, 7 hours 45 minutes ago

McFarlane Lake Announces Closing of Final Tranche of Upsized $1.3 Million Private Placement Offering
Published on 04/11/2025 at 02:00, 8 hours 25 minutes ago

Battery X Metals Announces Formation of Critical Battery Metals Exploration Subsidiary and Expansion of Quebec Exploration Portfolio with Acquisition of 39 Additional Mineral Claims
Published on 04/11/2025 at 00:00, 10 hours 25 minutes ago

Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research
Published on 04/10/2025 at 23:05, 11 hours 20 minutes ago

Caldwell Reports Second Quarter Results
Published on 04/10/2025 at 23:00, 11 hours 25 minutes ago

Highlander Silver Receives Conditional Approval to List on the TSX, Files Base Shelf Prospectus and Establishes ATM Program as Longer Term Financial Alternatives

View all ACCESSWIRE

EQS Group

Published on 04/11/2025 at 09:54, 31 minutes ago

Further letting success for ESPG AG: Emil Koch Group revitalises Science Park North43 in Cologne
Published on 04/11/2025 at 09:45, 40 minutes ago

Iute Group: Resumption of trading in the EUR 2021/2026 bond
Published on 04/11/2025 at 08:13, 2 hours 12 minutes ago

EQS-Adhoc: Mutares SE & Co. KGaA: Determination of the number of placed shares and the placement price in the private placement of shares in Steyr Motors AG
Published on 04/11/2025 at 08:00, 2 hours 24 minutes ago

EQS-Adhoc: BP p.l.c.: 1Q25 bp Trading Statement Part 1 of 1
Published on 04/11/2025 at 08:00, 2 hours 25 minutes ago

Annual Report and Notice of AGM

Les Echos

Published on 04/10/2025 at 17:45, 16 hours 40 minutes ago

EURAZEO INVESTS IN EKOSCAN INTEGRITY, A LEADING GLOBAL PROVIDER OF ADVANCED NON-DESTRUCTIVE TESTING SOLUTIONS FOR CRITICAL INDUSTRIAL APPLICATIONS AND INFRASTRUCTURE
Published on 04/10/2025 at 17:27, 16 hours 57 minutes ago

2024 URD - Universal Registration Document
Published on 04/09/2025 at 18:59, 1 day 15 hours ago

Description of the 2025-2026 Share Buyback Program
Published on 04/09/2025 at 18:57, 1 day 15 hours ago

Minutes of the Combined General Meeting held on April 9, 2025
Published on 04/09/2025 at 17:45, 1 day 16 hours ago

COGELEC : 2024 full-year results and Q1 2025 revenue.

View all LES ECHOS COMFI WIRE